SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (46)5/12/2001 6:59:44 PM
From: Miljenko Zuanic   of 1840
 
No, I do not think that FDA will turn them down. However, it may put restriction on label and promotion until further data become available.

Tarceva data for refractory NSCLC (monotherapy) are very good and seams that chance for promising first-line combination therapy are now much bigger. It will be interesting to see Iresa data for the some indication (it is their registration trial, now looks very reasonable approach).

Miljenko

PS: Link was mistake. AltaRex is going after sub-group, so it is not that positive.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News